Search research articles
Contact Us
Filters
Showing results (1-10 of 58) with videos related to
Page
of 6
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 22, 2009
Oncology drug review process
Ann T Farrell, Richard Pazdur
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2015
Acute Myeloid Leukemia Response Measures Other Than Complete Remission
Donna Przepiorka, Albert Deisseroth, Ann T Farrell
JAMA Oncology
|
September 16, 2016
Minimal Residual Disease as a Potential Surrogate End Point-Lingering Questions
Nicole J Gormley, Ann T Farrell, Richard Pazdur
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 8, 2005
Development of effective new treatments for multiple myeloma
Kenneth C Anderson, Richard Pazdur, Ann T Farrell
Blood
|
August 5, 2017
Flexibility and innovation in the FDA's novel regulatory approval strategies for hematologic drugs
Ann T Farrell, Kirsten B Goldberg, Richard Pazdur
Nature Clinical Practice. Urology
|
December 4, 2008
Expediting the availability of drugs for US patients with cancer
Ann T Farrell, Richard Pazdur, Andrew C von Eschenbach
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2006
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy
Robert C Kane, Ann T Farrell, Rajeshwari Sridhara, et al.
The Oncologist
|
March 19, 2010
The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology
Amy E McKee, Ann T Farrell, Richard Pazdur, et al.
The Oncologist
|
December 6, 2003
Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy
Robert C Kane, Peter F Bross, Ann T Farrell, et al.
British Journal of Haematology
|
June 27, 2007
A strategic framework for novel drug development in multiple myeloma
Kenneth C Anderson, Alison L Hannah, Richard Pazdur, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 58) with videos related to
Sort By:
Page
of 6
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 22, 2009
Oncology drug review process
Ann T Farrell, Richard Pazdur
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2015
Acute Myeloid Leukemia Response Measures Other Than Complete Remission
Donna Przepiorka, Albert Deisseroth, Ann T Farrell
JAMA Oncology
|
September 16, 2016
Minimal Residual Disease as a Potential Surrogate End Point-Lingering Questions
Nicole J Gormley, Ann T Farrell, Richard Pazdur
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 8, 2005
Development of effective new treatments for multiple myeloma
Kenneth C Anderson, Richard Pazdur, Ann T Farrell
Blood
|
August 5, 2017
Flexibility and innovation in the FDA's novel regulatory approval strategies for hematologic drugs
Ann T Farrell, Kirsten B Goldberg, Richard Pazdur
Nature Clinical Practice. Urology
|
December 4, 2008
Expediting the availability of drugs for US patients with cancer
Ann T Farrell, Richard Pazdur, Andrew C von Eschenbach
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2006
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy
Robert C Kane, Ann T Farrell, Rajeshwari Sridhara, et al.
The Oncologist
|
March 19, 2010
The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology
Amy E McKee, Ann T Farrell, Richard Pazdur, et al.
The Oncologist
|
December 6, 2003
Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy
Robert C Kane, Peter F Bross, Ann T Farrell, et al.
British Journal of Haematology
|
June 27, 2007
A strategic framework for novel drug development in multiple myeloma
Kenneth C Anderson, Alison L Hannah, Richard Pazdur, et al.
Page
of 6